Stevanato Group S.p.A. (STVN)
Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.2 per share a year ago.
STVN or MDGL: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Stevanato Group (STVN) or Madrigal (MDGL). But which of these two stocks offers value investors a better bang for their buck right now?
Stevanato: Structural Growth Intact, Buy Confirmed
Stevanato's biologics remain the core growth engine supported by a broad pipeline, resilient GLP-1 demand, vial recovery, and a favorable industry backdrop. While Engineering continues to weigh on margins in the short run, the weakness appears cyclical rather than structural, with optimization progressing and limited impact on group fundamentals. After a ~14% pullback, long-term earnings visibility remains strong, supporting higher 2026 profitability assumptions and a higher target price, leading us to maintain a constructive stance.
Stevanato Group S.p.A. (STVN) Q3 2025 Earnings Call Transcript
Stevanato Group S.p.A. ( STVN ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Lisa Miles - Chief Communications & Investor Relations Officer Franco Stevanato - CEO & Executive Chairman Marco Dal Lago - Chief Financial Officer Conference Call Participants Lawrence Solow - CJS Securities, Inc. Matthew Larew - William Blair & Company L.L.C.
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago.
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Stevanato Group S.p.A. (NYSE:STVN ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Marco Dal Lago - Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Securities, Research Division Presentation Michael Ryskin BofA Securities, Research Division I'm on the Bank of America Life Science Tools and Diagnostics team based out of New York.
Stevanato (STVN) Upgraded to Buy: Here's What You Should Know
Stevanato (STVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stevanato Group (STVN) Q2 Earnings and Revenues Beat Estimates
Stevanato Group (STVN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.1 per share a year ago.
Stevanato Group (STVN) Earnings Expected to Grow: Should You Buy?
Stevanato (STVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock?
Stevanato (STVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Stevanato: Expansion In Italy And The U.S. Will Pave The Way
The new facility in the U.S. expects to generate €500 million in annual revenues by 2028. The global drug containment solution market is expected to grow at an 8% CAGR from 2024 to 2030. In this market, Stevanato has a competitive advantage. Stevanato's PP&E has increased by 304.61% between 2018 and Q1 2025, indicating the significant investment that the company has dedicated to expanding its operations.
Stevanato: Recovery Underway, Buy Confirmed
Q1 results exceeded expectations, driven by strong Biopharmaceutical and Diagnostic Solutions growth and margin expansion from scaling new facilities. 2025 guidance was reaffirmed despite FX headwinds and Engineering division weakness. High-value products continue to support a robust profit outlook and with a positive sales guidance, we confirm our buy rating.
